What is the level of liabilities of Sartorius Stedim Biotech this year?
Sartorius Stedim Biotech has a debt balance of 5.1 B EUR this year.
In 2024, Sartorius Stedim Biotech's total liabilities amounted to 5.1 B EUR, a 95.02% difference from the 2.62 B EUR total liabilities in the previous year.
Sartorius Stedim Biotech's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Sartorius Stedim Biotech's financial stability, operational efficiency, and long-term viability.
By comparing Sartorius Stedim Biotech's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Sartorius Stedim Biotech's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Shifts in Sartorius Stedim Biotech’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Sartorius Stedim Biotech has a debt balance of 5.1 B EUR this year.
The liabilities of Sartorius Stedim Biotech have increased by 95.02% increased compared to the previous year.
High liabilities can pose a risk for investors of Sartorius Stedim Biotech, as they can weaken the company's financial position and impair its ability to meet its obligations.
Low liabilities mean that Sartorius Stedim Biotech has a strong financial position and is able to meet its obligations without overburdening its finances.
An increase in liabilities of Sartorius Stedim Biotech can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
A decrease in the liabilities of Sartorius Stedim Biotech can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
Some factors that can influence the liabilities of Sartorius Stedim Biotech include investments, acquisitions, operating costs, and sales development.
The liabilities of Sartorius Stedim Biotech are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
To change its liabilities, Sartorius Stedim Biotech can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
Over the past 12 months, Sartorius Stedim Biotech paid a dividend of 2.88 EUR . This corresponds to a dividend yield of about 1.5 %. For the coming 12 months, Sartorius Stedim Biotech is expected to pay a dividend of 3.69 EUR.
The current dividend yield of Sartorius Stedim Biotech is 1.5 %.
Sartorius Stedim Biotech pays a quarterly dividend. This is distributed in the months of April, April, April, May.
Sartorius Stedim Biotech paid dividends every year for the past 27 years.
For the upcoming 12 months, dividends amounting to 3.69 EUR are expected. This corresponds to a dividend yield of 1.93 %.
Sartorius Stedim Biotech is assigned to the 'Health' sector.
To receive the latest dividend of Sartorius Stedim Biotech from 4/4/2024 amounting to 0.69 EUR, you needed to have the stock in your portfolio before the ex-date on 4/2/2024.
The last dividend was paid out on 4/4/2024.
In the year 2023, Sartorius Stedim Biotech distributed 2.52 EUR as dividends.
The dividends of Sartorius Stedim Biotech are distributed in EUR.
The Sartorius Stedim Biotech stock can be added to a savings plan with the following providers: Trade Republic
Our stock analysis for Sartorius Stedim Biotech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sartorius Stedim Biotech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.